GSK buys autoimmune T cell engager for $300M upfront from Chimagen

As early data show how T cell engagers — originally developed for cancers — can potentially treat a range of autoimmune diseases, GSK is buying its own molecule from Chimagen Biosciences. The UK pharma is paying ...